STAT
@statnews.com
Reporting from the frontiers of health & medicine.
Explore all of our newsletters here: https://www.statnews.com/signup/
Explore all of our newsletters here: https://www.statnews.com/signup/
Pinned
STAT
@statnews.com
· 10d
Meet the 2026 STAT Wunderkinds
This year, as in past years, we've found inspiring stories and innovative research. All are blazing new trails as they attempt to answer some of the
www.statnews.com
This year, as in past years, we’ve found inspiring stories and innovative research. All are blazing new trails as they attempt to answer some of the biggest questions in science and medicine.
Meet the 2026 #STATWunderkinds!
https://www.statnews.com/wunderkinds/
Meet the 2026 #STATWunderkinds!
https://www.statnews.com/wunderkinds/
At the #STATSummit, former FDA chief Rob Califf shares his thoughts on DOGE.
October 16, 2026 at 8:03 PM
At the #STATSummit, former FDA chief Rob Califf shares his thoughts on DOGE.
Health agency workers, wary after DOGE-era layoffs, raise concerns over mandatory self-assessments and a cap on how many staffers are eligible for bonuses. https://www.statnews.com/2026/10/16/federal-performance-reviews-health-agency-employees-wary-after-doge/
In DOGE’s aftermath, federal health workers bristle at new performance reviews
Changes to the annual performance review process are the latest flashpoint in tensions between federal workers across the Department of Health and Human Services and the Trump administration, federal ...
www.statnews.com
October 16, 2026 at 7:02 PM
Health agency workers, wary after DOGE-era layoffs, raise concerns over mandatory self-assessments and a cap on how many staffers are eligible for bonuses. https://www.statnews.com/2026/10/16/federal-performance-reviews-health-agency-employees-wary-after-doge/
A schoolteacher diagnosed with melanoma provides an inside look at what it was like to be treated with a cancer vaccine developed by Merck and Moderna. https://www.statnews.com/2026/10/15/melanoma-diagnosis-mrna-cancer-vaccine-stat-summit-boston-2026/ #STATSummit
After a melanoma diagnosis, mRNA cancer vaccine delivered a patient hope — and a path forward
A schoolteacher diagnosed with melanoma provides an inside look at what it was like to be treated with a cancer vaccine developed by Merck and Moderna.
www.statnews.com
October 16, 2026 at 5:31 PM
A schoolteacher diagnosed with melanoma provides an inside look at what it was like to be treated with a cancer vaccine developed by Merck and Moderna. https://www.statnews.com/2026/10/15/melanoma-diagnosis-mrna-cancer-vaccine-stat-summit-boston-2026/ #STATSummit
At the #STATSummit, Adam Feuerstein asks Kailera CEO Ron Renaud about what it’s like to buy drug candidates from China, where Kailera got its portfolio:
October 15, 2026 at 11:22 PM
At the #STATSummit, Adam Feuerstein asks Kailera CEO Ron Renaud about what it’s like to buy drug candidates from China, where Kailera got its portfolio:
Is the market for obesity drugs saturated with Lilly and Novo offerings? Kailera CEO Ron Renaud, speaking at the #STATSummit, thinks not:
October 15, 2026 at 10:10 PM
Is the market for obesity drugs saturated with Lilly and Novo offerings? Kailera CEO Ron Renaud, speaking at the #STATSummit, thinks not:
Harvard researcher Paola Arlotta speaks at the #STATSummit about the progress made on organoids and the probability that there will be a major breakthrough on brain diseases using organoids in the next 10 years:
October 15, 2026 at 9:52 PM
Harvard researcher Paola Arlotta speaks at the #STATSummit about the progress made on organoids and the probability that there will be a major breakthrough on brain diseases using organoids in the next 10 years:
Michael D. Green, a postdoctoral fellow at Johns Hopkins School of Public Health and one of the plaintiffs suing the NIH over alleged freedom of speech infringements, talks about what it was like to have to change the direction of his research to abide by Trump administration rules. #STATSummit
October 15, 2026 at 9:09 PM
Michael D. Green, a postdoctoral fellow at Johns Hopkins School of Public Health and one of the plaintiffs suing the NIH over alleged freedom of speech infringements, talks about what it was like to have to change the direction of his research to abide by Trump administration rules. #STATSummit
The ACLU, Protect Democracy, and other organizations are representing researchers in a class action lawsuit alleging the NIH is infringing on their freedom of speech by screening grants for certain words and viewpoints when making funding decisions. We hear from one of the plaintiffs. #STATSummit
October 15, 2026 at 8:58 PM
The ACLU, Protect Democracy, and other organizations are representing researchers in a class action lawsuit alleging the NIH is infringing on their freedom of speech by screening grants for certain words and viewpoints when making funding decisions. We hear from one of the plaintiffs. #STATSummit
As the Trump administration pushes alternatives to animal research, one scientist is growing brain tissue in a dish and exploring the ethical questions it raises — including whether lab-grown organoids could have human rights. #STATSummit
October 15, 2026 at 8:16 PM
As the Trump administration pushes alternatives to animal research, one scientist is growing brain tissue in a dish and exploring the ethical questions it raises — including whether lab-grown organoids could have human rights. #STATSummit
If we want to lower drug prices, the biotech industry needs to take a hard look at which drugs make it out of Phase 1 trials and which ones don’t, says Institute for Clinical and Economic Review CEO Sarah Emond. #STATSummit
October 15, 2026 at 7:57 PM
If we want to lower drug prices, the biotech industry needs to take a hard look at which drugs make it out of Phase 1 trials and which ones don’t, says Institute for Clinical and Economic Review CEO Sarah Emond. #STATSummit
David Schenkein, general partner and life sciences lead at GV, and Jamil Beg, partner at SV Health Investors, talk about the competitive threats China poses to U.S. biotech companies. #STATSummit
October 15, 2026 at 7:16 PM
David Schenkein, general partner and life sciences lead at GV, and Jamil Beg, partner at SV Health Investors, talk about the competitive threats China poses to U.S. biotech companies. #STATSummit
Something Ventured
Venture capitalists have a well-worn playbook in the drug industry. But the rise of the Chinese biotech industry and the potential of AI are scrambling it. We hear how three top investors are responding to change. #STATSummit
Venture capitalists have a well-worn playbook in the drug industry. But the rise of the Chinese biotech industry and the potential of AI are scrambling it. We hear how three top investors are responding to change. #STATSummit
October 15, 2026 at 6:51 PM
Something Ventured
Venture capitalists have a well-worn playbook in the drug industry. But the rise of the Chinese biotech industry and the potential of AI are scrambling it. We hear how three top investors are responding to change. #STATSummit
Venture capitalists have a well-worn playbook in the drug industry. But the rise of the Chinese biotech industry and the potential of AI are scrambling it. We hear how three top investors are responding to change. #STATSummit
Chris Deacon, an insurance whistleblower, tells the #STATSummit that employers buying insurance have what she calls the “congressman problem.”
October 15, 2026 at 6:33 PM
Chris Deacon, an insurance whistleblower, tells the #STATSummit that employers buying insurance have what she calls the “congressman problem.”
Nearly half of Americans get health insurance through work, but rising costs are straining businesses and trapping workers in jobs they don’t want. We hear from a whistleblower who risked everything to challenge the system and urge employers to act. #STATSummit
![This image features a person wearing a light gray blazer and white shirt, standing against a blurred background. Next to them is a quote: “We can't consumer-shop our way out of the [health care] system that we've built.” Below the quote, it says "Chris Deacon, J.D., Founder and CEO, VerSan Consulting." The event logo "STAT Summit 2023" is visible in the corners.](https://cdn.bsky.app/img/feed_thumbnail/plain/did:plc:dawci6skpmelnlja3lygz3p7/bafkreifedofjpz4g2ud6hd2hjwbbszwf37dtbypyvuwvawt3hhpu4v47ti)
October 15, 2026 at 6:23 PM
Nearly half of Americans get health insurance through work, but rising costs are straining businesses and trapping workers in jobs they don’t want. We hear from a whistleblower who risked everything to challenge the system and urge employers to act. #STATSummit
As White House shifts focus toward AI and tech, U.S. science leaders defend role of the American university. MIT president worries about a ‘serious drought’ in curiosity-driven research. #STATSummit https://bit.ly/3VJ4YqA
As White House shifts focus toward AI and tech, U.S. science leaders defend role of the American university
White House planned shift of research funding from universities to industry risks creating a drought in basic research, science leaders say
www.statnews.com
October 15, 2026 at 5:20 PM
As White House shifts focus toward AI and tech, U.S. science leaders defend role of the American university. MIT president worries about a ‘serious drought’ in curiosity-driven research. #STATSummit https://bit.ly/3VJ4YqA
Stephen Hoge of Moderna talks about the partnership with Merck that produced an mRNA vaccine for cancer. #STATSummit
October 15, 2026 at 4:37 PM
Stephen Hoge of Moderna talks about the partnership with Merck that produced an mRNA vaccine for cancer. #STATSummit
You may know about the DOJ’s Health Care Fraud Unit and its high-profile convictions. But at #STATSummit, we learn how the unit is expanding, using technology, and targeting health care companies in Boston and Silicon Valley.
October 15, 2026 at 4:17 PM
You may know about the DOJ’s Health Care Fraud Unit and its high-profile convictions. But at #STATSummit, we learn how the unit is expanding, using technology, and targeting health care companies in Boston and Silicon Valley.
Cory Anderson balances his time between communities of Plain People and his position as an assistant professor of public health at the Penn State College of Medicine. He speaks at the #STATSummit about reimagining our idea of Amish and Mennonite vaccine hesitancy.
October 15, 2026 at 3:28 PM
Cory Anderson balances his time between communities of Plain People and his position as an assistant professor of public health at the Penn State College of Medicine. He speaks at the #STATSummit about reimagining our idea of Amish and Mennonite vaccine hesitancy.
Rep. Jake Auchincloss (D-Mass.) says when it comes to competing in biotech globally, Washington needs to “fix itself and worry less about what China is doing.” #STATSummit
October 15, 2026 at 2:51 PM
Rep. Jake Auchincloss (D-Mass.) says when it comes to competing in biotech globally, Washington needs to “fix itself and worry less about what China is doing.” #STATSummit
As biotech executive Christopher Viehbacher was helping roll out GSK’s Cervarix, there were a lot of questions the company didn’t think to ask, which he says made the rollout more difficult. #STATSummit
October 15, 2026 at 2:31 PM
As biotech executive Christopher Viehbacher was helping roll out GSK’s Cervarix, there were a lot of questions the company didn’t think to ask, which he says made the rollout more difficult. #STATSummit
Of Congress and Cures
The congressman for Massachusetts’ 4th district has defended biotech innovation, argued for legislation to help defend U.S. drugmakers against China, and fretted over the destabilization of the FDA. We hear his thoughts on the future. #STATSummit
The congressman for Massachusetts’ 4th district has defended biotech innovation, argued for legislation to help defend U.S. drugmakers against China, and fretted over the destabilization of the FDA. We hear his thoughts on the future. #STATSummit
October 15, 2026 at 2:21 PM
Of Congress and Cures
The congressman for Massachusetts’ 4th district has defended biotech innovation, argued for legislation to help defend U.S. drugmakers against China, and fretted over the destabilization of the FDA. We hear his thoughts on the future. #STATSummit
The congressman for Massachusetts’ 4th district has defended biotech innovation, argued for legislation to help defend U.S. drugmakers against China, and fretted over the destabilization of the FDA. We hear his thoughts on the future. #STATSummit
At the #STATSummit, three former leaders offered their advice on how the beleaguered agency can rebound from recent controversies. https://www.statnews.com/2026/10/14/former-fda-commissioners-say-recruit-defend-support-agency-workforce/
Former FDA officials blast DOGE as ‘one of the biggest disasters in American history’
Three former FDA chiefs criticized the DOGE cuts to the agency, saying they robbed the FDA of institutional knowledge that will take years to restore.
www.statnews.com
October 15, 2026 at 1:39 PM
At the #STATSummit, three former leaders offered their advice on how the beleaguered agency can rebound from recent controversies. https://www.statnews.com/2026/10/14/former-fda-commissioners-say-recruit-defend-support-agency-workforce/
Trust and Science
The scientific method is the best tool we have for arriving at truth. It is not much good for building trust — just look at the news. Is there a way to “science” our way to closing the trust gap? #STATSummit
The scientific method is the best tool we have for arriving at truth. It is not much good for building trust — just look at the news. Is there a way to “science” our way to closing the trust gap? #STATSummit
October 15, 2026 at 1:17 PM
Trust and Science
The scientific method is the best tool we have for arriving at truth. It is not much good for building trust — just look at the news. Is there a way to “science” our way to closing the trust gap? #STATSummit
The scientific method is the best tool we have for arriving at truth. It is not much good for building trust — just look at the news. Is there a way to “science” our way to closing the trust gap? #STATSummit
We're back for day two of our #STATSummit! Follow along for live updates!
October 15, 2026 at 12:54 PM
We're back for day two of our #STATSummit! Follow along for live updates!
Steven E. Hyman, Core Institute Member of the Broad Institute of MIT and Harvard, explains why psychedelics can offer quicker pathways to treatment for patients with depression than more traditional treatments. #STATSummit
October 14, 2026 at 11:00 PM
Steven E. Hyman, Core Institute Member of the Broad Institute of MIT and Harvard, explains why psychedelics can offer quicker pathways to treatment for patients with depression than more traditional treatments. #STATSummit